Results from a clinical trial of a new Alzheimer’s therapy look encouraging, but it remains to be seen how much the treatment can improve patients’ lives.
Earlier this week, the pharmaceutical companies Biogen and Eisai announced encouraging results from a clinical trial for patients with Alzheimer’s disease: a monoclonal antibody treatment, called lecanemab, reduced cognitive decline by 27% in people with early-stage Alzheimer’s compared with those on a placebo after a year and a half. Outside observers say the trial could offer hope to some of the millions of people afflicted worldwide, who are largely bereft of treatments.
. No other approved Alzheimer’s treatment targets the disease’s presumed roots, only its symptoms. Before aducanumab, U.S. officials hadn’t greenlighted an Alzheimer’s drug for almost 20 years.spoke with Alzheimer’s experts about this week’s announcement and what’s next for lecanemab and the field.shared outcomes of their study
Lecanemab had side effects, most notably certain brain abnormalities seen with other antiamyloid therapies, including swelling and small hemorrhages in the brain. Neuroimaging turned up these concerns in about 21% of patients on lecanemab, and 9% of those on the placebo. Although these abnormalities often produce no symptoms, about 3% of those getting lecanemab did have symptoms from them.
The trial also included only people who had evidence of amyloid in the brain—something that’s been true of more recent trials but not older ones studying antiamyloid therapies, De Strooper says.One notable feature of the lecanemab trial was that about 25% of its participants were either Black or Hispanic, a relatively high number in the world of clinical trials, where marginalized groups are woefully underrepresented.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Alzheimer's drug slowed progression of disease in late-stage study, drugmakers sayIn a widely-anticipated study, Eisai and Biogen on Tuesday said their Alzheimer's drug slowed cognitive decline among people with early signs of the disease.
Lire la suite »
Amylyx’s ALS Drug Is Approved by the FDARelyvrio, a new drug to treat ALS, has been approved by the FDA, giving patients a new option that may slow progression of the fatal degenerative disease
Lire la suite »
Alzheimer’s drug results are promising – but not a major breakthroughTrial results for a new medicine to treat Alzheimer’s disease have been described as a historic breakthrough and an unequivocal win for those with Alzheimer’s – but these claims are overblown on the evidence so far, says clarewilsonmed
Lire la suite »
Alzheimer's drug shows promise in early results of studyJapan's Eisai Co. said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. abc15
Lire la suite »
Alzheimer's drug shows promise in early results of studyShares of Biogen and other drugmakers researching Alzheimer’s disease have soared after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study.
Lire la suite »